At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 322 enrolled
Drug / intervention
efgartigimod PH20 SC in stage B +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
In Brief
A Phase 2 clinical trial evaluating efgartigimod PH20 SC in stage B and placebo in stage B for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Completed, enrolled 322 participants across 216 sites in 25 countries.
Detailed Summary
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russia, Serbia, Spain, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartApr 2020
Primary CompletionMay 2023
TodayJul 2026
First PostedFeb 24, 2020
Enrollment StartApr 15, 2020
Primary CompletionMay 11, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.4 years ago
Interventions
efgartigimod PH20 SC in stage Bbiological
Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
placebo in stage Bother
Stage A: N/A, stage B: placebo